Core Viewpoint - Cleveland-Cliffs Inc. (CLF) is expected to report first-quarter 2025 results on May 7, with anticipated challenges due to lower year-over-year steel prices despite cost-cutting measures and increased volumes [1][5][9]. Revenue Estimates - The Zacks Consensus Estimate for CLF's first-quarter consolidated revenues is $4,596.6 million, indicating an 11.6% year-over-year decline [4]. Performance Factors - CLF is likely to face headwinds from weaker steel prices, with benchmark hot-rolled coil (HRC) prices dropping over 40% last year, closing near $700 per short ton from $1,200 per short ton at the beginning of 2024 [5][6]. - The average net selling price per net ton of steel products is estimated at $986, reflecting a 16.1% year-over-year decrease [8]. Cost Management - The company is expected to benefit from reduced steelmaking unit costs, with a sequential decline of approximately $15 per ton in the fourth quarter of 2024 and an anticipated reduction of about $40 per net ton in 2025 compared to 2024 [9]. Volume Growth - CLF is projected to have experienced higher sales volumes in the March quarter, estimated at 4.06 million net tons, suggesting a 3% year-over-year increase, driven by automotive demand and contributions from the Stelco acquisition [10]. Earnings Prediction - The Earnings ESP for CLF is -25.19%, with the consensus estimate indicating a loss of 67 cents for the first quarter, suggesting a low probability of an earnings beat [11][12].

Core Viewpoint - Bunge Global SA (BG) is expected to report a significant decline in both sales and earnings for the first quarter of 2025, with sales estimated at $12.8 billion, a 4.5% decrease year-over-year, and earnings per share projected at $1.27, reflecting a 58% drop from the previous year [1] Financial Performance Estimates - The Agribusiness segment's revenues are estimated at $8.76 billion, down 10% from $9.74 billion in the prior year, with projected volumes of 19,369 thousand metric tons, a 4% decrease [4] - Adjusted EBIT for the Agribusiness segment is expected to be $206 million, a 58% decline year-over-year, with the merchandising business anticipated to see a 21% drop in EBIT to $60 million, and processing business EBIT projected to fall 68% to $133 million [5] - The Refined and Specialty Oils segment's revenues are estimated at $3.65 billion, indicating a 13% increase from the previous year, with operating income expected to drop 42% to $118 million [6][7] - The Milling segment's revenues are projected at $396 million, a 4% increase, with operating income estimated at $23 million, an 18% decline from the previous year [8] Impact of Segment Sales - The sale of the Sugar and Bioenergy segment, completed on October 1, 2024, is expected to negatively impact Bunge's income, as this non-core segment contributed $43 million in sales and $24 million in EBIT in the first quarter of 2024 [9] Stock Performance - Bunge's shares have increased by 14.3% over the past three months, outperforming the industry average growth of 2.2% [10]

Core Viewpoint - The Mosaic Company is expected to report its first-quarter 2025 results on May 6, with anticipated impacts from weak fertilizer prices but potential gains from healthy demand and cost-management actions [1]. Group 1: Earnings Performance - Mosaic has experienced a negative earnings surprise of approximately 17.2% on average over the last four quarters, with a 15.1% negative surprise in the most recent quarter [1]. - The Earnings ESP for Mosaic is +15.82%, with the Zacks Consensus Estimate for the first quarter set at 39 cents [4]. Group 2: Revenue Estimates - The Zacks Consensus Estimate for Mosaic's first-quarter consolidated sales is $2,665.9 million, indicating a decline of 0.5% compared to the same quarter last year [5]. Group 3: Market Conditions - Favorable demand for phosphate and potash is expected to benefit Mosaic, driven by strong agricultural conditions and favorable farmer economics globally [8]. - The demand for grains and oilseeds remains high, supporting the overall fertilizer market [8]. Group 4: Cost Management - Mosaic is implementing cost-reduction strategies aimed at achieving $150 million in run-rate cost reductions by the end of 2025 [9]. - The company is focused on improving its operating cost structure amid a challenging environment [9]. Group 5: Price Trends - Softer fertilizer prices have negatively impacted Mosaic's sales and margins, with phosphate and potash prices declining since mid-2022 [10]. - The average selling price per ton for the Potash segment is estimated at $209, reflecting a year-over-year decline of 29.6%, while the Phosphate unit's average selling price is expected to be $609, indicating a 10% decline from the prior year [11].

Core Viewpoint - DuPont de Nemours, Inc. is set to report its first-quarter 2025 results on May 2, with expectations of continued growth driven by innovation and acquisitions despite facing pricing headwinds [1][2]. Revenue Estimates - The Zacks Consensus Estimate for DuPont's first-quarter revenues is $3,040 million, reflecting a year-over-year increase of 3.7% [5]. - The Electronics & Industrial segment is expected to generate $1,479.8 million, indicating an 8.4% year-over-year rise, while the Water & Protection unit is projected at $1,293.6 million, suggesting a modest 0.2% increase [5]. Factors Influencing Performance - DuPont is anticipated to benefit from cost and productivity measures, as well as innovation-driven investments in high-growth areas [6]. - The company expects annualized cost savings of $150 million from ongoing restructuring actions [7]. - Recent acquisitions, including Spectrum Plastics Group and Donatelle Plastics, are likely to enhance DuPont's position in the healthcare market [8]. Pricing Challenges - DuPont has faced challenges from weak pricing in the first quarter, which impacted sales and margins, following a trend observed in the fourth quarter of 2024 [9]. Earnings Prediction Model - The current Earnings ESP for DuPont is -0.32%, and it holds a Zacks Rank of 4 (Sell), indicating uncertainty regarding an earnings beat this quarter [10][11].

Core Viewpoint - ICL Group is positioned to potentially continue its earnings-beat streak in upcoming reports, having surpassed earnings estimates significantly in recent quarters [1][5]. Earnings Performance - For the most recent quarter, ICL Group reported earnings of $0.08 per share, exceeding the expected $0.06 per share, resulting in a surprise of 33.33% [2]. - In the previous quarter, the company reported $0.11 per share against an expectation of $0.08 per share, leading to a surprise of 37.50% [2]. Earnings Estimates and Predictions - Estimates for ICL Group have been trending higher, influenced by its history of earnings surprises [5]. - The company currently has an Earnings ESP of +12.50%, indicating a bullish outlook from analysts regarding its earnings prospects [8]. - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a strong possibility of another earnings beat [8]. Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have a nearly 70% chance of producing a positive surprise [6]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7]. Importance of Earnings ESP - The Earnings ESP metric is crucial for predicting earnings performance, as a negative value can reduce its predictive power, but does not necessarily indicate an earnings miss [8]. - Companies often beat consensus EPS estimates, but share price movements can also be influenced by other factors [9].

Core Insights - Lavie Bio is a leader in the ag-biologicals industry with a strong pipeline of microbiome-based products, transferring key assets to ICL, including its core team, BDD technology platform, microbial bank, and most development programs [1][2][3] - The transaction is a result of over two years of collaboration between ICL and Lavie Bio, aimed at developing bio-stimulant solutions for crops under abiotic stress [2][3] - The integration of Lavie Bio into ICL is expected to significantly advance the ag-biologicals field and drive innovation in agriculture [3] Company Overview - Lavie Bio, a subsidiary of Evogene Ltd., focuses on enhancing food quality and agricultural productivity through microbiome-based products, utilizing a proprietary computational predictive platform powered by Evogene's MicroBoost AI technology [4] - Evogene Ltd. is a computational biology company that aims to revolutionize life-science product development through advanced technologies, including MicroBoost AI, ChemPass AI, and GeneRator AI, which are designed for discovering and developing products based on microbes, small molecules, and genetic elements [6]

德方纳米与ICL分别持有该厂20%和80%的股份，合作双方也分别对此项目发表相关言论。 经历业绩大起大落的德方纳米迎来开门红。 起点锂电获悉， 德方纳米与特种矿物公司ICL集团达成协议，将在西班牙加泰罗尼亚萨伦特镇 合资建设锂电池材料工厂 ，该厂投资为2.85亿欧元，占地约25英亩，与当地规划的电池厂距离 较近，是西班牙该地区第一家生产磷酸铁锂材料的工厂。 德方纳米任望保表示磷酸铁锂是锂电池的关键材料，对新能源汽车产业链完善至关重要，合资 是双方优势的有利整合；ICL菲尔 布朗（Phil Brown）则认为磷酸铁锂是能源转型的关键解决 方案将共同开发一个重要的新增长市场。 ICL Group Ltd.主营特种矿物，主要有溴、钾肥和磷酸盐等产品，主打食品、农业、工业市场 相关矿物解决方案。近年来该公司对新能源领域有浓郁兴趣，除本次项目外，还在美国密苏里 州建立大型的磷酸铁锂制造厂。 德方纳米同样出海意愿强烈，海外布局方面此前公司表示称对海外情况进行充分考察与分析， 将选择合适的时间推进出海计划，本次合作是公司出海过程中具有里程碑意义的事件，标志公 司向外迈出了关键一步。 01 抗住市场压力，稳步前行 德方纳米一 ...